Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

Webcast ImageWebcast
AcelRx Pharmaceuticals, Inc. at the Jefferies 2015 Healthcare Conference (Replay)
06/01/15 at 4:00 p.m. ET
AcelRx Pharmaceuticals, Inc. at the Jefferies 2015 Healthcare Conference
Monday, June 1, 2015 4:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
PDF File ACRX Corporate Presentation - 5/7/15
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.
ACRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.67
Change (%) Stock is Up 0.04 (1.10%)
Volume318,662
Data as of 06/02/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

    More >>
05/22/15AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June
REDWOOD CITY, Calif., May 22, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that interim chief executive officer Howie Rosen will be presenting at Jefferies 2015 Healthcare Conference and chief financial officer Tim Morris will be presenting at JMP Securities Life Science Conference. Details of the two pr... 
Printer Friendly Version
05/14/15AcelRx Awarded Contract from Department of Defense to Advance ARX-04
REDWOOD CITY, Calif., May 14, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced it has entered into Contract No. W81XWH-15-C-0046 worth up to $17.0 million, supported by the United States Army Medical Research and Materiel Command (USAMRMC) within the U.S. Department of Defense (DoD). The contract provides partial f... 
Printer Friendly Version
05/04/15AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results
REDWOOD CITY, Calif., May 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided a regulatory update on Zalviso and reported financial results for the three months ended March 31, 2015. Zalviso Regulatory Update On April 21, 2015, AcelRx submitted a request to the Division of Anesthesia, Analgesia, and Add... 
Printer Friendly Version

Upcoming Events

    More >>
DateTitle
06/24/15 9:00 a.m. ET
AcelRx Pharmaceuticals, Inc. at the JMP Securities Life Science Conference
LocationSt Regis Hotel
New York, NY

Receive E-mail Alerts 

Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AcelRX

CONTACT